158 related articles for article (PubMed ID: 21473913)
41. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
42. Validation of putative genomic biomarkers of nephrotoxicity in rats.
Wang EJ; Snyder RD; Fielden MR; Smith RJ; Gu YZ
Toxicology; 2008 Apr; 246(2-3):91-100. PubMed ID: 18289764
[TBL] [Abstract][Full Text] [Related]
43. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
[TBL] [Abstract][Full Text] [Related]
44. Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers.
Keirstead ND; Wagoner MP; Bentley P; Blais M; Brown C; Cheatham L; Ciaccio P; Dragan Y; Ferguson D; Fikes J; Galvin M; Gupta A; Hale M; Johnson N; Luo W; McGrath F; Pietras M; Price S; Sathe AG; Sasaki JC; Snow D; Walsky RL; Kern G
Toxicol Sci; 2014 Feb; 137(2):278-91. PubMed ID: 24189134
[TBL] [Abstract][Full Text] [Related]
45. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients.
Kaplinsky E; González-Costello J; Manito N; Roca J; Barbosa MJ; Nebot M; Salazar-Mendiguchia J; Berdejo J; Mañas P; Miralles A; Cequier A
Transplant Proc; 2012 Nov; 44(9):2564-6. PubMed ID: 23146455
[TBL] [Abstract][Full Text] [Related]
46. Calcineurin inhibitors nephrotoxicity revisited.
Pallet N
Am J Transplant; 2021 Sep; 21(9):2929-2930. PubMed ID: 33797862
[No Abstract] [Full Text] [Related]
47. Drug-induced acute kidney injury.
Schetz M; Dasta J; Goldstein S; Golper T
Curr Opin Crit Care; 2005 Dec; 11(6):555-65. PubMed ID: 16292059
[TBL] [Abstract][Full Text] [Related]
48. Metabonomics for discovering biomarkers of hepatotoxicity and nephrotoxicity.
Zhang A; Sun H; Wang P; Han Y; Wang X
Pharmazie; 2012 Feb; 67(2):99-105. PubMed ID: 22512077
[TBL] [Abstract][Full Text] [Related]
49. [Drug nephrotoxicity].
Izzedine H
Nephrol Ther; 2018 May; 14(3):127-134. PubMed ID: 29540291
[TBL] [Abstract][Full Text] [Related]
50. The epidemiology of drug-induced disorders: the kidney.
Taber SS; Pasko DA
Expert Opin Drug Saf; 2008 Nov; 7(6):679-90. PubMed ID: 18983215
[TBL] [Abstract][Full Text] [Related]
51. A Review on Drug-Induced Nephrotoxicity: Pathophysiological Mechanisms, Drug Classes, Clinical Management, and Recent Advances in Mathematical Modeling and Simulation Approaches.
Mody H; Ramakrishnan V; Chaar M; Lezeau J; Rump A; Taha K; Lesko L; Ait-Oudhia S
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):896-909. PubMed ID: 33025766
[TBL] [Abstract][Full Text] [Related]
52. AJKD Atlas of Renal Pathology: Calcineurin Inhibitor Nephrotoxicity.
Lusco MA; Fogo AB; Najafian B; Alpers CE
Am J Kidney Dis; 2017 May; 69(5):e21-e22. PubMed ID: 28434526
[No Abstract] [Full Text] [Related]
53. Role of Klotho in Chronic Calcineurin Inhibitor Nephropathy.
Luo K; Lim SW; Quan Y; Cui S; Shin YJ; Ko EJ; Chung BH; Yang CW
Oxid Med Cell Longev; 2019; 2019():1825018. PubMed ID: 31772699
[TBL] [Abstract][Full Text] [Related]
54. Does Mineralocorticoid Receptor Antagonism Prevent Calcineurin Inhibitor-Induced Nephrotoxicity?
Mortensen LA; Bistrup C; Thiesson HC
Front Med (Lausanne); 2017; 4():210. PubMed ID: 29226122
[TBL] [Abstract][Full Text] [Related]
55. The 6R's of drug induced nephrotoxicity.
Awdishu L; Mehta RL
BMC Nephrol; 2017 Apr; 18(1):124. PubMed ID: 28372552
[TBL] [Abstract][Full Text] [Related]
56. Use of transcriptomics in understanding mechanisms of drug-induced toxicity.
Cui Y; Paules RS
Pharmacogenomics; 2010 Apr; 11(4):573-85. PubMed ID: 20350139
[TBL] [Abstract][Full Text] [Related]
57. Emerging therapy-related kidney disease.
Arend LJ; Nadasdy T
Arch Pathol Lab Med; 2009 Feb; 133(2):268-78. PubMed ID: 19195969
[TBL] [Abstract][Full Text] [Related]
58. The introduction of toxicogenomics; potential new markers of hepatotoxicity.
Heijne WH; Stierum RH; Leeman WR; van Ommen B
Cancer Biomark; 2005; 1(1):41-57. PubMed ID: 17192031
[No Abstract] [Full Text] [Related]
59. Diagnosis of drug-induced renal tubular toxicity using global gene expression profiles.
Jiang Y; Gerhold DL; Holder DJ; Figueroa DJ; Bailey WJ; Guan P; Skopek TR; Sistare FD; Sina JF
J Transl Med; 2007 Oct; 5():47. PubMed ID: 17908307
[TBL] [Abstract][Full Text] [Related]
60. Recent successes in the identification, development, and qualification of translational biomarkers: the next generation of kidney injury biomarkers.
Ennulat D; Adler S
Toxicol Pathol; 2015 Jan; 43(1):62-9. PubMed ID: 25492424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
